These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 7032772

  • 1. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
    Fiorilli M, Sirianni MC, Pandolfi F, Quinti I, Tosti U, Aiuti F, Goldstein G.
    Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
    [Abstract] [Full Text] [Related]

  • 2. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
    Joffe MI, Sochett E, Pettifor JM, Rabson AR.
    J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
    [Abstract] [Full Text] [Related]

  • 3. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F, Businco L, Fiorilli M, Galli E, Quinti I, Le Moli S, Seminara R, Goldstein G.
    Birth Defects Orig Artic Ser; 1983 May; 19(3):267-72. PubMed ID: 6360238
    [No Abstract] [Full Text] [Related]

  • 4. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ, Davies EG, Goldstein G.
    Birth Defects Orig Artic Ser; 1983 May; 19(3):273-6. PubMed ID: 6360239
    [No Abstract] [Full Text] [Related]

  • 5. NK cell function in severe combined immunodeficiency (SCID): evidence of a common T and NK cell defect in some but not all SCID patients.
    Peter HH, Friedrich W, Dopfer R, Müller W, Kortmann C, Pichler WJ, Heinz F, Rieger CH.
    J Immunol; 1983 Nov; 131(5):2332-9. PubMed ID: 6415162
    [Abstract] [Full Text] [Related]

  • 6. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F, Businco L, Fiorilli M, Galli E, Quinti I, Rossi P, Seminara R, Goldstein G.
    Lancet; 1983 Mar 12; 1(8324):551-4. PubMed ID: 6131256
    [Abstract] [Full Text] [Related]

  • 7. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G, Zöch G, Rath T, Meissl G.
    Prog Clin Biol Res; 1989 Mar 12; 308():995-9. PubMed ID: 2528748
    [No Abstract] [Full Text] [Related]

  • 8. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
    Cooper KD, Kang K, Hanifin JM.
    Diagn Immunol; 1983 Mar 12; 1(3):211-5. PubMed ID: 6388971
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of monoclonal antibodies in the diagnosis and monitoring of patients with primary immunodeficiencies: combined experience in three clinical immunology centers.
    Aiuti F, Quinti I, Seminara R, Sirianni MC, Vierucci A, Abo T, Cooper MD.
    Diagn Immunol; 1983 Mar 12; 1(3):188-94. PubMed ID: 6388970
    [Abstract] [Full Text] [Related]

  • 10. Phenotypical and functional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency.
    Takagi S, Minakuchi J, Okawa H, Yata J.
    J Clin Immunol; 1989 Jan 12; 9(1):39-47. PubMed ID: 2649508
    [Abstract] [Full Text] [Related]

  • 11. Preliminary results on clinical and immunological effects of thymopentin in AIDS.
    Clumeck N, van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J.
    Int J Clin Pharmacol Res; 1984 Jan 12; 4(6):459-63. PubMed ID: 6398315
    [Abstract] [Full Text] [Related]

  • 12. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A, D'Aniello C, Falotico N, Saletti M, Di Perri T.
    Recenti Prog Med; 1986 Sep 12; 77(9):423-8. PubMed ID: 3541085
    [No Abstract] [Full Text] [Related]

  • 13. Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects.
    Businco L, Rossi P, Paganelli R, Galli E, DiGilio G, Lulli P, Aiuti F.
    Clin Immunol Immunopathol; 1984 Oct 12; 33(1):123-30. PubMed ID: 6383671
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro enhancement of bone marrow natural killer cells after incubation with thymopoietin32-36 (TP-5).
    Fiorilli M, Sirianni MC, Sorrentino V, Testi R, Aiuti F.
    Thymus; 1983 Sep 12; 5(5-6):375-82. PubMed ID: 6197787
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.
    DeMaubeuge J, Haneke E, Djawari D, Wolff K, Stingl G, Molin L, Schöpf E, Stengel R, Degreef H, Panconesi E.
    Surv Immunol Res; 1985 Sep 12; 4 Suppl 1():30-6. PubMed ID: 2863860
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response to thymopoietin pentapeptide in patient with DiGeorge syndrome.
    Aiuti F, Businco L, Rossi P, Quinti I.
    Lancet; 1980 Jan 12; 1(8159):91. PubMed ID: 6101433
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.